CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.
CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.
复制标题
DOI：
10.1158/1078-0432.ccr-14-2900
复制
发表时间：
2015-08-15
期刊：
影响因子：
--
通讯作者：
Ellis LM
中科院分区：
文献类型：
--
作者：
Camp ER;Ellis LM
临床数据支持EGFR mAb用于野生型RAS状态的转移性结直肠癌（mCRC）患者。这个概念，假设在评论文章中由坎普，埃利斯，和同事在2005年1月1日，临床癌症研究问题，作为一个例子，成功地应用基本科学原则的临床实践。从EGFR mAb治疗中排除Ras突变肿瘤的mCRC患者，改善了结局，同时节省了患者不必要和潜在有害的治疗。
Clinical data support the use of EGFR mAbs in patients with metastatic colorectal cancer (mCRC) with wild-typeRAS status. This notion, hypothesized in the review article by Camp, Ellis, and colleagues in the January 1, 2005, issue of Clinical Cancer Research, serves as an example of the successful application of basic science principles to clinical practice. The exclusion of patients with mCRC with Ras mutated tumors from therapy with EGFR mAbs has led to improved outcomes while sparing patients unnecessary and potentially harmful therapy.